AI-extracted from the 10-K filed 2026-08-26 — FY2026 (year ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
Phibro's net sales grew 17% YoY to $1,518M, driven by the Animal Health segment (+21%) and the ramp of the Zoetis MFA acquisition, pushing Adjusted EBITDA up 39% to $255M.
Biggest Revenue Drivers
Animal Health$1,162M+21% YoY
Growth driven by MFAs and other products, including contribution from the acquired Zoetis MFA portfolio
Mineral Nutrition$282M+11% YoY
Biggest Revenue Drivers
Total revenue: $1,518M+17% YoY
Animal Health$1,162M+21% YoY
Growth driven by MFAs and other products, including contribution from the acquired Zoetis MFA portfolio
Within Animal Health
MFAs and other$811M+25% YoY
Includes $358.2M from the acquired Zoetis medicated feed additive product portfolio
Nutritional specialties$195M+9% YoY
Mineral Nutrition$282M+11% YoY
Performance Products$74M-8% YoY
Margins: Adjusted EBITDA rose 39% to $255M with the Animal Health segment contributing 91% of segment EBITDA (before corporate costs), while Corporate costs increased 12% to $78M, partially offsetting segment-level gains.
Watch Items from the Filing
Medicated products (antibacterials and related) accounted for approximately 54% of net sales in FY2026, up from 50% in FY2025, concentrating risk in a category subject to regulatory restriction.
On April 27, 2026, Brazil's MAPA banned virginiamycin and bacitracin for performance enhancement (180-day transition); Brazilian virginiamycin sales were approximately $27 million in FY2026.
FDA is pursuing withdrawal of carbadox (Mecadox) approval; sales were approximately $21 million in FY2026, with Phibro litigating in D.C. Federal District Court to invalidate the FDA's order.
Israeli operations represent 18% of consolidated assets and 16% of net sales as of FY2026, amid ongoing regional conflict risk; Brazil represents 12% of assets and 12% of net sales.
Company will close its Chicago Heights, Illinois manufacturing facility (shutdown expected summer 2027) as part of a plant network consolidation; financial impact not yet estimable.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
About PHIBRO ANIMAL HEALTH CORP (PAHC): stock profile, AI score and financials
PHIBRO ANIMAL HEALTH CORP (PAHC) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores PAHC at 64.6/100 on a composite quality score built from its SEC filings, placing it at rank #528 of 2,925 stocks — the top 25% of the AI-ranked universe. PAHC scores in the top quartile across revenue growth (82.5), balance sheet strength (76.9). Areas of concern include free cash flow (29.1), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q4 2026), PHIBRO ANIMAL HEALTH CORP reports quarterly revenue of $396.7M, net income of $21.7M, an operating margin of 12.1%. Top institutional holders of PAHC by reported 13-F value include BlackRock, FMR, STATE STREET, based on the most recent SEC filings. PAHC trades on the Nasdaq exchange and files with the SEC under CIK 1069899. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PAHC daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for PHIBRO ANIMAL HEALTH CORP directly from SEC EDGAR.